Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 497 Rectal Neoplasms 268 Colonic Neoplasms 219 Pancreatic Neoplasms 188 Stomach Neoplasms 183 Esophageal Neoplasms 135 Breast Neoplasms 119 Neoplasm Metastasis 117 Squamous Cell Carcinoma of Head and Neck 95 Head and Neck Neoplasms 92 Neoplasms 90 Adenocarcinoma Of Esophagus 67 Esophageal Squamous Cell Carcinoma 62 Carcinoma, Hepatocellular 56 Adenocarcinoma 40 Nasopharyngeal Carcinoma 35 Cholangiocarcinoma 32 Biliary Tract Neoplasms 27 Anus Neoplasms 26 Gastrointestinal Neoplasms 25 Carcinoma, Squamous Cell 25 Carcinoma, Non-Small-Cell Lung 25 Keratosis, Actinic 23 Gallbladder Neoplasms 22 Liver Neoplasms 21 Urinary Bladder Neoplasms 20 Parkinson Disease 4, Autosomal Dominant Lewy Body 20 Bile Duct Neoplasms 19 Ovarian Neoplasms 16 Carcinoma 16

Interventions

Gemcitabine 4 130-nm albumin-bound paclitaxel 2 sintilimab 1 nimotuzumab 1 avelumab 1 Taxes 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Hydroxychloroquine 1 Fluorouracil 1 Capecitabine 1 Antineoplastic Agents 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Cancer Resectable × Fluorouracil × Clear all

NCT07155629 2025-09-04

LEFT-PANC

Helsinki University Central Hospital

Phase 3 Not yet recruiting

Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon ⚡